Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Sep 15:4:244.
doi: 10.3389/fonc.2014.00244. eCollection 2014.

Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials

Barbara Melosky  1
Affiliations
Review

Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials

Barbara Melosky. Front Oncol. .

Abstract

Recent clinical trials have demonstrated the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) in the treatment of patients with advanced metastatic non-small cell lung cancer. Most of these recent trials were conducted in patients with EGFR mutation-positive tumors. As our knowledge of the EGFR mutation and its resistant pathways develops, the complexity of the situation expands. This article briefly reviews the pivotal trials leading to approval of EGFR TKIs in the first-line setting for patients with EGFR mutation-positive non-small cell lung carcinomas. It discusses the historical use of EGFR TKIs after the first-line setting in unselected patients and briefly describes ongoing trials.

Keywords: EGFR TKI; afatinib; dacomitinib; erlotinib; first-line therapy; gefitinib.

PubMed Disclaimer

References

    1. Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ, Kurzrock R. Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol (2011) 6(9):1601–12 10.1097/JTO.0b013e31822944b3 - DOI - PubMed
    1. Zhang X, Chang A. Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci (2008) 5(4):209–17 10.7150/ijms.5.209 - DOI - PMC - PubMed
    1. Sebastian M, Schmittel A, Reck M. First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology. Eur Respir Rev (2014) 23(131):92–105 10.1183/09059180.00008413 - DOI - PMC - PubMed
    1. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J-Y, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer. J Clin Oncol (2003) 21(12):2237–46 10.1200/JCO.2003.10.038 - DOI - PubMed
    1. Kris MG, Natale RB, Herbst RS, Lynch TJ, Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA (2003) 290(16):2149–58 10.1001/jama.290.16.2149 - DOI - PubMed